Psychopharmacology and Psychiatry Updates

In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 84
Benzodiazepine Tapering: Key Takeaways From New Guidelines

In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations

In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why?
Faculty: Paul Zarkowski, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 83
Can GLP-1 Agonists Elevate Lithium Levels?

In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety

In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 83
Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial